SNX-111 neuron-specific calcium channel blocker: FDA lifted the hold placed on NXCO's Phase II trials due to recumbent hypotension that had been occurring with

Neurex Corp. (NXCO), Menlo Park, Calif. Product: SNX-111 neuron-specific calcium channel blocker Indication: Prevent brain damage after closed head trauma, and coronary bypass surgery Status: FDA li...